Mizuho raised the firm’s price target on Wave Life Sciences (WVE) to $22 from $19 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm says Wave Life remains a potential secular growth story for 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE: